Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

No Place like Home: Home-Based Intravenous Arsenic Trioxide for the Treatment of Acute Promyelocytic Leukemia (APL)

Brooke Kania, David Awad, Michael Kane, Andrew M Evens, Neil Palmisiano

Blood (2023) 142 (Supplement 1): 2357.

https://doi.org/10.1182/blood-2023-190597

Published: 2023

Journal Articles

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Talha Badar, Ehab L. Atallah, Rory M. Shallis, Anand Ashwin Patel, Guilherme Sacchi De Camargo Correia, Aaron D. Goldberg, Antoine Saliba, Jan Philipp Bewersdorf, Adam S Duvall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Vamsi K. Kota, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 592.

https://doi.org/10.1182/blood-2023-184626

Published: 2023

Journal Articles

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Gina Keiffer, Sara E. Meyer, Christine Eischen, Ubaldo Martinez Outschoorn, Onder Alpdogan, Adam F. Binder, Pierluigi Porcu, Lindsay Wilde, Margaret Kasner, Neil Palmisiano

Blood (2023) 142 (Supplement 1): 1551.

https://doi.org/10.1182/blood-2023-186765

Published: 2023

Journal Articles

Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation

Talha Badar, Ravi Narra, Alice Mims, Rory M. Shallis, Guilherme Sacchi De Camargo Correia, Cameron Hunter, Vamsi K. Kota, Shreya Desai, Anand Ashwin Patel, Adam S Duvall, Neil Palmisiano, Emily K Curran, Omer Zulfa, Anjali S. Advani, Ehab L. Atallah, Mark R. Litzow

Blood (2023) 142 (Supplement 1): 1464.

https://doi.org/10.1182/blood-2023-188188

Published: 2023

Journal Articles

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Gina Keiffer, Guneet Kaleka, Caspian Oliai, Lindsay Wilde, Neil Palmisiano, Margaret Kasner

Blood (2022) 140 (Supplement 1): 3320–3321.

https://doi.org/10.1182/blood-2022-170710

Published: 2022

Journal Articles

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Molly Halloran, Gina Keiffer, Veda Giri, Laura Gross, Lindsay Wilde, Neil Palmisiano, Pierluigi Porcu, Margaret Kasner

Blood (2022) 140 (Supplement 1): 11466–11467.

https://doi.org/10.1182/blood-2022-165510

Published: 2022

Journal Articles

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 6058–6060.

https://doi.org/10.1182/blood-2022-163795

Published: 2022

Journal Articles

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Blood (2022) 140 (Supplement 1): 1716–1719.

https://doi.org/10.1182/blood-2022-157326

Published: 2022

Journal Articles

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow

Blood (2022) 140 (Supplement 1): 1435–1437.

https://doi.org/10.1182/blood-2022-167731

Published: 2022

Journal Articles

Smoking and Its Prognostic Effect on Survival in Patients with TP53 Mutated MDS

Sean Patrick Reilly, Xia Bi, Zachary French, Lindsay Wilde, Neil Palmisiano

Blood (2022) 140 (Supplement 1): 12339–12340.

https://doi.org/10.1182/blood-2022-164712

Published: 2022

Journal Articles

A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication

Blood (2021) 138 (Supplement 1): 50.

https://doi.org/10.1182/blood-2021-149728

Published: 2021

Journal Articles

Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

Neil Palmisiano, Ju-Whei Lee, David F. Claxton, Elisabeth Paietta, Hassan B. Alkhateeb, Jae H Park, Nikolai Podoltsev, Ehab L. Atallah, Dale G Schaar, Shira Dinner, Jonathan Webster, Selina M. Luger, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2021-153621

Published: 2021

Journal Articles

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

Manish R. Patel, Varun Monga, Shekeab Jauhari, Don Stevens, Lucia Masarova, Meredith McKean, David Mauro, John Viscusi, Peggy Scherle, Neha Bhagwat, Andrew Moore, William Sun, Rachel Chiaverelli, Eric Mintah, Rajneesh Nath, Eytan M. Stein, Neil Palmisiano, Grerk Sutamtewagul, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 2609.

https://doi.org/10.1182/blood-2021-150938

Published: 2021

Journal Articles

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio

Blood (2021) 137 (3): 374–386.

https://doi.org/10.1182/blood.2020006926

Published: 2021

Includes: Supplemental data

Journal Articles

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Chetan Jeurkar, DO, Benjamin E Leiby, PhD, Joshua Banks, MS, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Joanne Filicko-O'Hara, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-133837

Published: 2020

Journal Articles

Vaccination Response after Autologous Stem Cell Transplantation

Onder Alpdogan, MD, Jennifer Hong, MD, Thomas R. Klumpp, MD, Abdullateef O Abdulkareem, MD MPH, Adam F. Binder, MD, Matthew Carabasi, MD, Joanne Filicko-O'Hara, MD, Dolores Grosso, DNP, CRNP, Margaret Kasner, MDMSc, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Lindsay Wilde, MD, Pierluigi Porcu, MD, Usama Gergis, MD, John L. Wagner, MD, Neal Flomenberg, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-141269

Published: 2020

Journal Articles

Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML

Lindsay Wilde, MD, Ubaldo Martinez-Outschoorn, MD, Neil Palmisiano, MDMS, Gina Keiffer, MD, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-140729

Published: 2020

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

Journal Articles

Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Xia Bi, MD MS, Zachary French, MD, Margaret Kasner, MDMSc, Gina Keiffer, MD, Lindsay Wilde, MD, Neil Palmisiano, MDMS

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141640

Published: 2020

Journal Articles

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Gina Keiffer, MD, Kelly Hughes, Tingting Zhan, PhD, Lindsay Wilde, MD, Neil Palmisiano, MDMS, Margaret Kasner, MDMSc

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140055

Published: 2020

NARROW

No Place like Home: Home-Based Intravenous Arsenic Trioxide for the Treatment of Acute Promyelocytic Leukemia (APL)

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

A Phase Ib/II Study Evaluating Navitoclax after Failure of Hypomethylating Agent and Venetoclax for Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Achievement of Undetectable BCR::ABL1 (uBCR::ABL1) Is Predictive of Improved Survival in Philadelphia Chromosome Positive (Ph+ve) Acute Lymphoblastic Leukemia (ALL) Patients Not Receiving Allogeneic Stem Cell Transplantation

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Assessment of Concurrent Personal and Family History of Hematologic Malignancies in Patients Referred for Genetic Counseling at Thomas Jefferson University Hospital (TJUH), Sidney Kimmel Cancer Center (SKCC) from 2014-2021

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Smoking and Its Prognostic Effect on Survival in Patients with TP53 Mutated MDS

A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication

Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Inpatient Versus Outpatient Hypomethylating Agent Induction for AML As a Predictor for Survival

Vaccination Response after Autologous Stem Cell Transplantation

Results of the Phase 1b Dose Escalation Study of OPB-111077, Decitabine, and Venetoclax for the Treatment of Newly Diagnosed or Relapsed/Refractory AML

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Impact of Smoking and TP53 Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML) Is Safe and Yields Healthcare Resource Savings

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only